Welcome to our dedicated page for First Northwest SEC filings (Ticker: FNWB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
First Northwest Bancorp’s strength lies in the details of its balance sheet—details tucked inside hundreds of pages of SEC disclosures. Whether you’re comparing residential loan growth to commercial real-estate exposure or watching how a shifting rate cycle affects net interest margin, every answer starts here.
Stock Titan’s platform brings those answers forward. Our AI turns the First Northwest Bancorp annual report 10-K simplified into an executive-ready brief, flags shifts in allowance for credit losses inside each First Northwest Bancorp quarterly earnings report 10-Q filing, and decodes First Northwest Bancorp 8-K material events explained within minutes of hitting EDGAR. Curious about director purchases? Receive instant alerts for First Northwest Bancorp Form 4 insider transactions real-time and review historical First Northwest Bancorp insider trading Form 4 transactions without scrolling through PDFs.
Common questions are answered as you read: “How do I interpret FNWB’s proxy statement executive compensation?� Our summaries point you straight to pay-for-performance metrics. Need quick context on capital ratios or loan concentration? Tap our AI-powered highlights labeled “understanding First Northwest Bancorp SEC documents with AI.� For deeper dives, compare trend charts generated from First Northwest Bancorp earnings report filing analysis.
All filing types update the moment they post�10-K, 10-Q, 8-K, S-3, and the complete set of First Northwest Bancorp executive stock transactions Form 4. No spreadsheets to download, no jargon to untangle; just clear insights so you can focus on decisions, not document hunting.
Schedule 13D/A highlights Tang Capital Management, Kevin Tang and affiliated investment vehicles disclosed updated ownership and transaction details regarding Cargo Therapeutics, Inc. ("CRGX").
- Beneficial ownership: The reporting group controls 3,059,630 common shares, representing 6.6 % of the 46,113,353 shares outstanding. Voting and dispositive power over the shares is shared among Tang Capital Management, Tang Capital Partners (TCP), Tang Capital Partners International (TCPI) and Kevin Tang.
- Source of funds: Approximately $22 million of working capital from TCP and TCPI, held in margin accounts, was used to acquire the stake.
- New strategic development � signed Merger Agreement (7 July 2025):
- Buyer: Concentra Biosciences, LLC; vehicle: Concentra Merger Sub VII, Inc.
- Tender-offer price: $4.379 in cash per CRGX share plus one contingent value right (CVR).
- Subsequent merger: Merger Sub will merge into Cargo Therapeutics, with Cargo surviving as a Concentra subsidiary.
- Key closing conditions: (i) >50 % of outstanding shares tendered; (ii) Closing Net Cash � $217.5 million; (iii) customary regulatory and procedural conditions.
- Limited guaranty: TCP provided a guarantee capped at $213.1 million for certain obligations under the Merger Agreement.
- CVR structure: Holders will be entitled to (i) 100 % of Closing Net Cash above $217.5 million, and (ii) 80 % of net proceeds from any sale, transfer or license of CRG-022, CRG-023 or the company’s allogeneic platform occurring within two years post-merger, subject to a $250 k expense cap.
- No recent trading activity: The reporting persons executed no CRGX share transactions during the past 60 days.
The amendment primarily informs investors of the cash-and-CVR takeover proposal, outlines financial protections (guaranty, cash threshold) and updates the group’s unchanged 6.6 % ownership position.